Page last updated: 2024-12-11

15-hydroperoxy-5,8,11,13-eicosatetraenoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

## 15-Hydroperoxy-5,8,11,13-eicosatetraenoic acid (15-HPETE)

15-HPETE is a **lipid peroxide**, specifically a **hydroperoxy eicosatetraenoic acid**, derived from the **arachidonic acid pathway**. It plays a crucial role in various physiological and pathological processes.

**Here's a breakdown:**

* **Arachidonic acid pathway:** This pathway is triggered by various stimuli, including inflammation, injury, and infection. It leads to the production of various bioactive lipid mediators, including prostaglandins, thromboxanes, leukotrienes, and lipoxins.
* **15-HPETE formation:** 15-HPETE is formed by the action of **15-lipoxygenase (15-LOX)**, an enzyme that catalyzes the oxygenation of arachidonic acid at the 15th carbon position.
* **Importance in research:** 15-HPETE is a **key intermediate** in the biosynthesis of other bioactive lipid mediators, particularly **lipoxins**. Lipoxins have anti-inflammatory properties and are involved in resolving inflammation. This makes 15-HPETE a crucial molecule in understanding the complex regulation of inflammation.

**Here are some specific areas where 15-HPETE research is important:**

* **Inflammation:** 15-HPETE is involved in both the initiation and resolution of inflammation, making it a potential target for therapeutic interventions.
* **Cardiovascular disease:** Studies suggest that 15-HPETE may play a role in the pathogenesis of cardiovascular disease.
* **Cancer:** 15-HPETE has been implicated in both tumor growth and suppression, highlighting its complex involvement in cancer biology.
* **Neurological disorders:** Some research indicates 15-HPETE may be involved in the pathogenesis of neurodegenerative diseases.

**Future research on 15-HPETE will likely focus on:**

* Elucidating its precise role in various physiological and pathological processes.
* Developing novel therapies targeting 15-HPETE for the treatment of inflammatory, cardiovascular, and other diseases.

**In summary, 15-HPETE is a crucial molecule in the arachidonic acid pathway, influencing inflammation, cardiovascular health, and other physiological processes. Further research is needed to fully understand its complex role and potential therapeutic applications.**

15-hydroperoxy-5,8,11,13-eicosatetraenoic acid: RN given refers to cpd without isomeric designation; (S-(E,Z,Z,Z))-isomer caused dose-dependent constriction of cat coronary arteries; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

15-HPETE : A HPETE that consists of (5Z,8Z,11Z,13E)-icosatetraenoic acid in which the hydroperoxy group is located at position 15. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6437084
CHEBI ID91271
SCHEMBL ID7718097
MeSH IDM0084047

Synonyms (38)

Synonym
5,8,11,13-eicosatetraenoic acid, 15-hydroperoxy-, (5z,8z,11z,13e)-
33r5u5v88c ,
69371-38-6
unii-33r5u5v88c
15hpete
15-hydroperoxy-5,8,11,13-eicosatetraenoic acid, (e,z,z,z)-isomer
15-hpete
15-hydroperoxy-5,8,11,13-eicosatetraenoic acid
14,15-epoxyarachidonic acid
15-hpaa
15-hpea
arachidonic acid 15-hydroperoxide
5,8,11,13-eicosatetraenoic acid, 15-hydroperoxy-
15-hydroperoxyarachidonic acid
15-hydroperoxy-5,8,11,13-eicosatetraenoic acid, (z,z,z,z)-isomer
15-hydroperoxy-5,8,11,13-eicosatetraenoic acid, (s)-(e,z,z,z)-isomer
67675-14-3
(5z,8z,11z,13e)-15-hydroperoxyicosa-5,8,11,13-tetraenoic acid
CHEBI:91271
15-hydroperoxy-(5z,8z,11z,13e)-eicosatetraenoic acid
(5z,8z,11z,13e)-15-hydroperoxyicosatetraenoic acid
15-hydroperoxy-(5z,8z,11z,13e)-icosatetraenoic acid
SCHEMBL7718097
(5z,8z,11z,13e)-15-hydroperoxy-5,8,11,13-icosatetraenoic acid
(5z,8z,11z,13e)-15-hydroperoxyeicosa-5,8,11,13-tetraenoic acid
(rs)-15-hpete
15-hydroperoxyeicosatetraenoic acid, (5z,8z,11z,13e,15rs)-
15-hydroperoxyarachidonic acid, (rs)-
15-hpete, (rs)-
15-hydroperoxy-(5z,8z,11z,13e)-eicosatetraenoate
15-hydroperoxy-(5z,8z,11z,13e)-icosatetraenoate
LMFA03060102
15-hydroperoxy-(z,z,z,e)-5,8,11,13-eicosatetraenoic acid
(6e,8z,11z,14z)-15-hydroperoxyicosatetraenoate
15-hydroperoxy-5,8,11,13-eicosatetraenoate
(6e,8z,11z,14z)-15-hydroperoxyicosatetraenoic acid
Q27163177
DTXSID101318726

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In the presence of 1 X 10(-3) M fusaric acid, the dose-response curves of cerebral arteries for 15-HPAA were antagonized in a noncompetitive manner."( Contractile responses of mammalian cerebral arteries to 15-hydroperoxyarachidonic acid vary in the presence of fusaric acid and verapamil.
Asano, M; Hidaka, H; Matsuda, T; Suzuki, Y, 1984
)
0.27
" Dose-response studies indicated that 5-HPETE was a potent (IC25 = 10(-8) M) inhibitor of Na+, K(+)-ATPase activity."( 5-HPETE is a potent inhibitor of neuronal Na+, K(+)-ATPase activity.
Foley, TD, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
HPETEMono-hydroperoxy (e)icosatetraenoic acids (HPETEs) are the primary products of lipoxygenase-catalysed oxygenation of arachidonic acid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Arachidonic acid (AA, ARA) oxylipin metabolism076

Research

Studies (295)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990168 (56.95)18.7374
1990's81 (27.46)18.2507
2000's37 (12.54)29.6817
2010's6 (2.03)24.3611
2020's3 (1.02)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.53 (24.57)
Research Supply Index5.72 (2.92)
Research Growth Index4.25 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews14 (4.62%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other289 (95.38%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]